Alkermes plc. (ALKS) company profile
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
About Alkermes
Pharmaceutical Preparations, SIC 2834
Alkermes plc is a biopharmaceutical company focusing on treatments for neurological and psychiatric conditions. Its proprietary commercial portfolio includes Aristada and Aristada Initio for schizophrenia, Lybalvi for schizophrenia and bipolar I disorder, Vivitrol for alcohol and opioid dependence, and Lumryz for narcolepsy. Additionally, the company licenses proprietary formulations to corporate partners, including Janssen for antipsychotics and Biogen for multiple sclerosis. Its products serve adult and pediatric patients with chronic diseases, as well as certified healthcare professionals and pharmacies.
Headquartered in Ireland, Alkermes operates a corporate office and research facility in Massachusetts, alongside a manufacturing site in Wilmington, Ohio. While the company commercializes its proprietary drugs in the United States, its licensed products are distributed globally through partner networks across the European Union and other international regions.
Summary of the business section of Alkermes's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alkermes plc.
- Headquarters
- Dublin 4, L2
- Address
- Connaught House, 1 Burlington Road 00000
- Phone
- 00-353-1-772-8000
- Website
- alkermes.com
- Employees
- 2,050, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ALKS
- Exchange
- Nasdaq
- IPO date
- Jul 16, 1991
- Shares outstanding
- 168M, Jul 23, 2026
- Public float
- $4.66B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, May 15, 2000
- SEC CIK
- 1520262
- CUSIP
- G01767105
- FIGI
- BBG000C9F2F9
- Share class FIGI
- BBG001S6RXM7
- EIN
- 98-1007018
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Blair Curtis Jackson | President & CEO, Alkermes plc, Director | 241,308 |
| Richard F. Pops | Director and CEO, Alkermes plc | 1,439,970 |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 219,353 |
| Joshua Reed | SVP, Chief Financial Officer | 5,095 |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 |
| Christian Todd Nichols | SVP, Chief Commercial Officer | 102,857 |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 11,109 |
| Iain Michael Brown | SVP, Chief Financial Officer | 148,196 |
| Anne Clem Whitaker | Director | – |
| nancy lynn snyderman MD | Director | 64,126 |
| Christopher I. Wright | Director | 25,680 |
| Frank Anders Wilson | Director | 35,751 |
| Shane Cooke | Director | 106,679 |
| Cato T. Laurencin | Director | 33,769 |
| Brian P. McKeon | Director | 48,536 |
| Richard Gaynor | Director | 37,226 |
| Nancy Lurker | Director | 19,697 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.92M | $12.59M | $3.54M | $143 | $125 |
| FY2024 | $10.13M | $14.63M | $3.90M | $147 | $93 |
| FY2023 | $9.44M | $8.98M | $4.03M | $141 | $94 |
| FY2022 | $10.31M | $8.32M | $4.16M | $131 | $90 |
| FY2021 | $8.85M | $11.23M | $2.94M | $117 | $100 |
| FY2020 | $8.04M | $6.88M | $2.88M | $98 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Richard F. Pops Chief Executive Officer and Chairman | $1.25M | – | $5.02M | $1.63M | $17.50K | $7.92M | -22% |
| Joshua Reed Senior Vice President, Chief Financial Officer | $181.98K | $1.16M | $2.33M | $118.29K | $7.69K | $3.80M | – |
| Blair C. Jackson Executive Vice President, Chief Operating Officer; Former Interim Principal Financial Officer | $736.45K | $1.33M | $1.32M | $618.62K | $17.50K | $4.03M | -18% |
| David J. Gaffin Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $684.50K | $1.10M | $1.09M | $574.98K | $17.50K | $3.47M | -16% |
| Craig C. Hopkinson, M.D. Executive Vice President, Research and Development and Chief Medical Officer | $764.84K | $1.10M | $1.09M | $642.46K | $17.50K | $3.62M | -17% |
| C. Todd Nichols Senior Vice President, Chief Commercial Officer | $614.87K | $866.68K | $861.23K | $430.41K | $17.50K | $2.79M | -16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 20, 2026, we had approximately 2,050 full time employees, of which approximately 1,950 were based in the U.S.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?